Reduction of cisplatin dosage by ZD 1839HAMBEK, Markus; BAGHI, Mehran; STREBHARD, Klaus et al.Anticancer research. 2005, Vol 25, Num 6B, pp 3985-3988, issn 0250-7005, 4 p.Article

Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agentsCIARDIELLO, Fortunato.Drugs (Basel). 2000, Vol 60, pp 25-32, issn 0012-6667, SUP1Article

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839ALBANELL, Joan; ROJO, Federico; BASELGA, José et al.Seminars in oncology. 2001, Vol 28, Num 5, pp 56-66, issn 0093-7754, SUP16Conference Paper

Epidermal Growth Factor Receptor-Targeted Approaches for Anticancer Therapy: Focus on ZD1839ARTEAGA, Carlos L.Drugs (Basel). 2000, Vol 60, issn 0012-6667, 46 p., SUP1Serial Issue

A sensitive assay for ZD1839 (Iressa¹) in human plasma by liquid liquid extraction and high performance liquid chromatography with mass spectrometric detection: Validation and use in phase I clinical trialsJONES, H. K; STAFFORD, L. E; SWAISLAND, H. C et al.Journal of pharmaceutical and biomedical analysis. 2002, Vol 29, Num 1-2, pp 221-228, issn 0731-7085Article

Resistance to gefitinib in PTEN-null her-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/AKT pathway signalingSHE, Qing-Bai; SOLIT, David; BASSO, Andrea et al.Clinical cancer research. 2003, Vol 9, Num 12, pp 4340-4346, issn 1078-0432, 7 p.Article

ZD1839 ('Iressa')^1,2 as an anticancer agentBASELGA, José; AVERBUCH, Steven D.Drugs (Basel). 2000, Vol 60, pp 33-40, issn 0012-6667, SUP1Article

Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosisSUZUKI, Hiroko; AOSHIBA, Kazutetsu; YOKOHORI, Naoko et al.Cancer research (Baltimore). 2003, Vol 63, Num 16, pp 5054-5059, issn 0008-5472, 6 p.Article

Nouvelles cibles de traitement dans le cancer du poumon: Rôle des inhibiteurs de tyrosine kinase EGF-R = New target in lung cancer treatmentSOLIGNAC, M; AVERBUCH, S.Revue de pneumologie clinique (Paris). 2000, pp 3S34-3S36, issn 0761-8417, SUP3Conference Paper

Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinomaDRUCKER, Beverly; BACIK, Jennifer; GINSBERG, Michelle et al.Investigational new drugs. 2003, Vol 21, Num 3, pp 341-345, issn 0167-6997, 5 p.Article

Combination of a selective cyclooxygenase-2 inhibitor with Epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effectsTORTORA, Giampaolo; CAPUTO, Rosa; DAMIANO, Vincenzo et al.Clinical cancer research. 2003, Vol 9, Num 4, pp 1566-1572, issn 1078-0432, 7 p.Article

CYFRA 21-I level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapyBARLESI, F; TCHOUHADJIAN, C; DODDOLI, C et al.British journal of cancer. 2005, Vol 92, Num 1, pp 13-14, issn 0007-0920, 2 p.Article

Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. CommentaryFUJIWARA, Keiichi; KIURA, Katsuyuki; UEOKA, Hiroshi et al.Lung cancer. 2003, Vol 40, Num 1, pp 73-78, issn 0169-5002, 6 p.Article

Récepteurs EGF dans les cancers urologiques : Bases moléculaires et implications thérapeutiques = EGF receptors in urological cancer. Molecular basis and therapeutic involvementsPAULE, Bernard; BRION, Nathalie.Annales de médecine interne (Paris). 2003, Vol 154, Num 7, pp 448-456, issn 0003-410X, 9 p.Article

ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinaseHIRATA, Akira; OGAWA, Soh-Ichiro; KOMETANI, Takuro et al.Cancer research (Baltimore). 2002, Vol 62, Num 9, pp 2554-2560, issn 0008-5472Article

ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapyWAKELING, Alan E; GUY, Simon P; WOODBURN, Jim R et al.Cancer research (Baltimore). 2002, Vol 62, Num 20, pp 5749-5754, issn 0008-5472, 6 p.Article

Epithelial growth factor receptor interacting agentsBASELGA, Jose; ALBANELL, Joan.Hematology/oncology clinics of North America. 2002, Vol 16, Num 5, issn 0889-8588, v, 1041-1063 [24 p.]Article

Expérience française du géfitinib dans le cancer bronchique non à petites cellules : Efficacité et tolérance en traitement compassionnel = French experience of gefitinib in non-small cell bronchial carcinomaGIRARD, N; GERINIERE, L; BLANDIN, S et al.Revue des maladies respiratoires. 2004, Vol 21, Num 5, pp 934-942, issn 0761-8425, 9 p., CAH1Article

The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic indexSHE, Yuhong; LEE, Fei; CHEN, Jing et al.Clinical cancer research. 2003, Vol 9, Num 10, pp 3773-3778, issn 1078-0432, 6 p., 1Article

Chemotherapy of Non-small cell lung cancer in elderly patientsGRIDELLI, C; MAIONE, P; COLANTUONI, G et al.Current medicinal chemistry. 2002, Vol 9, Num 16, pp 1487-1495, issn 0929-8673Article

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteersSWAISLAND, Helen; LAIGHT, Alison; STAFFORD, Lesley et al.Clinical pharmacokinetics. 2001, Vol 40, Num 4, pp 297-306, issn 0312-5963Article

ZD1839 (IRESSA), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of egfr-positive cancer cell lines with or without ERBB2 overexpressionANDERSON, Neil G; AHMAD, Tawhid; CHAN, Kai et al.International journal of cancer. 2001, Vol 94, Num 6, pp 774-782, issn 0020-7136Article

The tyrosine kinase inhibitor ZD1839 (iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cellsMOASSER, Mark M; BASSO, Andrea; AVERBUCH, Steven D et al.Cancer research (Baltimore). 2001, Vol 61, Num 19, pp 7184-7188, issn 0008-5472Article

ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four casesCAPPUZZO, F; CALANDRI, C; BARTOLINI, S et al.British journal of cancer. 2003, Vol 89, Num 2, pp 246-247, issn 0007-0920, 2 p.Article

A pharmacodynamic study of the Epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patientsDANESHMAND, Manijeh; PAROLIN, Doris A. E; LORIMER, Ian A. J et al.Clinical cancer research. 2003, Vol 9, Num 7, pp 2457-2464, issn 1078-0432, 8 p.Article